Product logins

Find logins to all Clarivate products below.


Tolebrutinib

Learn how tolebrutinib is changing the multiple sclerosis (MS) landscape.

What is tolebrutinib and what sets it apart

Tolebrutinib is a potential first-in-class, brain-penetrant Bruton tyrosine kinase (BTK) inhibitor developed for MS. By crossing the blood-brain barrier, it achieves therapeutic exposure in the CNS, enabling direct modulation of B-lymphocytes and disease-associated microglia that drive smoldering neuroinflammation and therefore disability accumulation.

This novel mechanism distinguishes it from conventional MS therapies, which largely focus on peripheral inflammation. By addressing the core inflammatory processes underlying progressive MS, tolebrutinib could slow neurodegeneration, offering a transformative advance in treating a disease with high unmet need.

About tolebrutinib

  • Company: Sanofi
  • Type: BTK inhibitor
  • Usage: Once-daily oral administration to treat non-relapsing secondary progressive-MS (nrSP-MS)
  • When will tolebrutinib be available?
    Expected launch 2026: European Union, United States
    Expected launch 2027: Japan

Tolebrutinib sales and success forecasts

$1.4bn
expected sales in the G7 markets in 2031
95%
probability of success for tolebrutinib in the United States

You basically have a drug that shows effectiveness in a cohort that is harder to treat, and you have a drug that shows equal effectiveness to teriflunomide, which is a standard first-line level agent.

Neurologist United States

Drugs in the 2026 list